Clinical trials: Liver Malignancy
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer
Study of Metatinib Tromethamine Tablet
This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver…
- Conditions
- Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer, Advanced or Metastatic CRC, Advanced or Metastatic Non Squamous NSCLC
- Trial name
- NCT02650375
- Testing
- Metatinib Tromethamine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma (HCC)
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU…
- Trial name
- NCT02508467
- Testing
- Fisogatinib (BLU-554)
- Where
- 41 sites in United States, China and 10 more
- Volunteers
- 146 people
- Sponsor
- Blueprint Medicines Corporation
Liver Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
- Trial name
- NCT02013830
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 7 sites in Australia, Hong Kong and 2 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult, Impaired Liver Function
Oral Docetaxel in Patients With Normal or Impaired Liver Function
This is an open label, single centre pharmacological and safety study to define the safety and pharmacokinetics of ModraDoc006/r in a weekly dosing schedule in patients with impaired liver function who might have benefit from a…
- Trial name
- NCT05084456
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Sponsor
- Modra Pharmaceuticals
Hepatic Insufficiency, Renal Insufficiency
Study of Copanlisib in Hepatic or Renal Impairment
To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects
- Trial name
- NCT03172884
- Testing
- Copanlisib (ALIQOPA, BAY80-6946)
- Where
- 2 sites in Germany, Romania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer